Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,954 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00047216 | Tipifarnib in Treating Patients With Recurrent Bladder Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT00066352 | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | completed | Phase 2 | — | University Health Network, TorontoOTHER | 2 | Jul 23, 2015 | clinicaltrials |
| NCT02505516 | BLADDER CANCER SCREENING AMONG DIABETIC PATIENTS | completed | Early Phase 1 | 150 | UFUOMA MILLER FAKPOROTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00734994 | Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer | completed | Early Phase 1 | 15 | Mark DewhirstOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT01314664 | A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC) | terminated | — | 15 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Jun 12, 2015 | clinicaltrials |
| NCT01316874 | Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)(Bladder Cancer) | completed | Phase 2 / Phase 3 | 90 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Jun 12, 2015 | clinicaltrials |
| NCT01374789 | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer(PURO) | terminated | Phase 2 | 2 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00082719 | Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT02443844 | Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression | unknown | Phase 4 | 40 | Diskapi Teaching and Research HospitalOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT01600339 | A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) | completed | Phase 2 | 19 | Rambam Health Care CampusOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT02278978 | BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma | unknown | Phase 2 | 129 | National Taiwan University HospitalOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT01526486 | Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | completed | N/A | 29 | Emory UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT02007005 | Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 37 | Abnoba GmbhINDUSTRY | 2 | May 6, 2015 | clinicaltrials |
| NCT02422277 | Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy | unknown | Phase 2 | 60 | Mansoura UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00019435 | LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00785694 | Recurrence of Bladder Cancer After Transurethral Resection With Hexvix | withdrawn | Phase 4 | 0 | GE HealthcareINDUSTRY | 1 | Apr 24, 2015 | clinicaltrials |
| NCT02186925 | A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney. | unknown | — | 1,000 | Meir Medical CenterOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00949455 | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium(LaMB) | unknown | Phase 2 / Phase 3 | 204 | Queen Mary University of LondonOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00933374 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma(RAD001) | terminated | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT00918008 | A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer | terminated | — | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT02006667 | A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 13 | Hoffmann-La RocheINDUSTRY | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01498172 | BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients | completed | Phase 1 | 23 | Patrice JichlinskiOTHER | 1 | Feb 4, 2015 | clinicaltrials |
| NCT02345473 | Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy(CirCanCell) | completed | — | 59 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT02345499 | Open Versus Laparoscopic Radical Cystectomy(OvsL) | unknown | Phase 2 | 80 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00136175 | Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder | completed | Phase 2 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02139371 | Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography | completed | Early Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Dec 12, 2014 | clinicaltrials |
| NCT01087697 | Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit | completed | Phase 1 | 8 | TengionINDUSTRY | 1 | Dec 10, 2014 | clinicaltrials |
| NCT00393796 | Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma | terminated | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00384891 | Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | terminated | Phase 3 | 190 | Medical Enterprises Europe B.V.INDUSTRY | 4 | Oct 7, 2014 | clinicaltrials |
| NCT00544609 | Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent(SOGUG-07-01) | completed | Phase 1 | 10 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Oct 2, 2014 | clinicaltrials |
| NCT01487915 | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma(COACH) | unknown | Phase 2 | 80 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT02013765 | A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Sep 25, 2014 | clinicaltrials |
| NCT02238886 | Radical Cystectomy, Nutrition and Convalescence | completed | N/A | 36 | Rigshospitalet, DenmarkOTHER | 1 | Sep 12, 2014 | clinicaltrials |
| NCT01284205 | First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC | withdrawn | Phase 3 | 0 | Bioniche Life Sciences Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00634621 | Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer | completed | — | 283 | GE HealthcareINDUSTRY | 1 | Aug 25, 2014 | clinicaltrials |
| NCT02174185 | Compare the Quality of Life Between Patients With Conduit Diversions or Orthotopic Neobladders | unknown | — | 300 | Huazhong University of Science and TechnologyOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT00213655 | URO-BCG-4 : Bladder Tumors Immunotherapy | completed | — | 146 | University Hospital, RouenOTHER | 1 | Jul 31, 2014 | clinicaltrials |
| NCT01688414 | Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer | withdrawn | N/A | 0 | Stanford UniversityOTHER | 0 | Jul 29, 2014 | clinicaltrials |
| NCT00313599 | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 28 | University of California, San FranciscoOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00623064 | Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 1 | 18 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 1, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00471536 | Pazopanib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | May 30, 2014 | clinicaltrials |
| NCT01711112 | Salvage Docetaxel for Pretreated Urothelial Cancer | completed | Phase 2 | 31 | Samsung Medical CenterOTHER | 1 | May 15, 2014 | clinicaltrials |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | Apr 29, 2014 | clinicaltrials |
| NCT01240824 | Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer(BCG) | completed | Early Phase 1 | 3 | University of VirginiaOTHER | 1 | Apr 14, 2014 | clinicaltrials |
| NCT02113501 | Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: a Prospective Observational Cohort Study | completed | — | 200 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Apr 14, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2015source: clinicaltrials